Cited by 272Metabolism, Diabetes, and CancerPeroxisome Proliferator-Activated ReceptorsAdipose Tissue and Metabolism

Minireview: Malonyl CoA, AMP-Activated Protein Kinase, and Adiposity

Ruderman, Neil B., Saha, Asish K., Kraegen, Edward W.·2003·Endocrinology

Abstract

An increasing body of evidence has linked AMP-activated protein kinase (AMPK) and malonyl coenzyme A (CoA) to the regulation of energy balance. Thus, factors that activate AMPK and decrease the concentration of malonyl CoA in peripheral tissues, such as exercise, decrease triglyceride accumulation in the adipocyte and other cells. The data reviewed here suggest that this is related to the fact that these factors concurrently increase fatty acid oxidation, decrease the esterification of fatty acids to form glycerolipids, and, by mechanisms still unknown, increase energy expenditure. Malonyl CoA contributes to these events because it is an allosteric inhibitor of carnitine palmitoyltransferase, the enzyme that controls the transfer of long-chain fatty acyl CoA from the cytosol to the mitochondria, where they are oxidized. AMPK activation in turn increases fatty acid oxidation (by effects on enzymes that govern malonyl CoA synthesis and possibly its degradation) and inhibits triglyceride synthesis. It also increases the expression of uncoupling proteins and the transcriptional regulator peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC1alpha), which could possibly increase energy expenditure. Recent studies suggest that the ability of leptin, adiponectin, 5'-aminoimidazole 4-carboxamide riboside (AICAR), adrenergic agonists, and metformin to diminish adiposity may be mediated, at least in part, by AMPK activation in peripheral tissues. In addition, preliminary studies suggest that malonyl CoA and AMPK take part in fuel-sensing and signaling mechanisms in the hypothalamus that could regulate food intake and energy expenditure.

Integrity signals

Registry

Crossref · 10.1210/en.2003-0849

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The safety issue of using AICAR or other drugs targeting AMPK needs to be considered.

    “While these data suggest a potential use of these compounds in improving skeletal muscle function and increasing energy expenditure, the safety issue of using AICAR or other drugs targeting AMPK needs to be considered 162.”

    From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [162]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ruderman, N. B., Saha, A. K., & Kraegen, E. W.
Affiliations
  • Boston University (US)
  • Garvan Institute of Medical Research (AU)
Corresponding author
Ruderman, Neil B.
Venue
Endocrinology
Published
2003-12
Volume
144
Issue
12
Pages
5166-5171
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2055061083
Cited by
266
References
54
Citations by year
2026: 1 · 2024: 2 · 2023: 5 · 2022: 8 · 2021: 10 · 2020: 5 · 2019: 10 · 2018: 7 · 2017: 6 · 2016: 8 · 2015: 12 · 2014: 11 · 2013: 8 · 2012: 26
FWCI
7.01
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01dk019514-35)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK-19514)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
Keywords
malonyl-CoA, AMPK, adiposity, energy balance, fatty acid oxidation, carnitine palmitoyltransferase, triglyceride synthesis, uncoupling proteins, PGC-1α, leptin, adiponectin, AICAR, metformin, sympathomimetic drugs, food intake regulation, energy expenditure
MeSH terms
Adipose Tissue, Animals, Humans, Malonyl Coenzyme A, Multienzyme Complexes, Obesity, Protein Serine-Threonine Kinases, AMP-Activated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review